Abstract Library

#4641 Case series: Tuberous sclerosis associated pancreatic neuroendocrine tumours at a tertiary centre

Introduction: Tuberous sclerosis (TSC) is an autosomal dominant condition which can increase the risk of pancreatic neuroendocrine tumours (PanNETs) (1). Patients with TSC undergo screening for renal tumours which may include pancreatic imaging (2). There are currently no screening guidelines for PanNETs in patients with TSC.

Conference:

Presenting Author: Frydman A

Authors: Frydman A, Clement D, Srirajaskanthan R,

Keywords: Pancreas neuroendocrine tumour, Tuberous sclerosis,

#3761 Tuberous sclerosis (TSC) mutations in patients with pancreatic neuroendocrine neoplasms are associated with distinct pathological, radiological and treatment-related findings

Introduction: Patients with pancreatic neuroendocrine neoplasms (PanNENs) can rarely harbour tuberous sclerosis (TSC) mutations but there is no knowledge on the pathological, radiological or treatment-related associations of those.

Conference:

Presenting Author: Navale P

Authors: Navale P, Itani M, Trikalinos N,

Keywords: TSC, temozolomide, oncocytic, PanNEN,

#40 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients

Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, heterogeneous, and with variable biological behavior. NETs can be sporadic or they can arise in complex endocrine hereditary syndromes such as Multiple Endocrine Neoplasias (MEN), Familial Paragangliomatosis (FPGL), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease (VHL), Tuberous Sclerosis (TSC) and Carney Complex (CC). By performing genetic screening, patients with hereditary NETs can be identified before the development of tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Faggiano A, Ramundo V, Milone F, Severino R, Lombardi G,

Keywords: neuroendocrine tumor, genetic analysis, MEN1, MEN2, paragangliomatosis, genotype-phenotype correlation.,